In a preclinical trial in small cell lung cancer, the use of the JAK/STAT inhibitor lusolidin effectively increased viral replication, and the killing effect of VSV-IFN-β on tumor cells was enhanced in vitro conditions. This evidence concerns the gene IFNB1 and neoplasm.